Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Next Previous
X
Search
Trial Profile

Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms KEYNOTE-030
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 12 Mar 2017 Results (n=315) of KEYNOTE-001,KEYNOTE-002, KEYNOTE-006 and one expanded acces phase II study assessing clinicopathological factors in PD-1 antibodies response published in the British Journal of Cancer.
    • 15 Nov 2016 Results of retrospective analysis from pooled data of this and other five studies (n=60) published in the Cancer.
    • 12 Oct 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top